Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SeaStar Medical Holding Corporation (Nasdaq: ICU) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings give investors detailed information about SeaStar Medical’s commercial-stage healthcare business built around its Selective Cytopheretic Device (SCD) therapy and QUELIMMUNE (SCD-PED) product for pediatric acute kidney injury (AKI).
Through Form 8-K current reports, SeaStar Medical discloses material events such as the recommendation of an independent Data Safety Monitoring Review Board to continue the NEUTRALIZE-AKI pivotal trial with zero device-related safety issues, changes in executive leadership, and corporate actions like the approval and implementation of a 1-for-10 reverse stock split to adjust the company’s share structure while maintaining its Nasdaq listing. These filings also describe adjustments to clinical trial enrollment targets and other operational updates.
The company’s DEF 14A proxy statements provide details on matters submitted to stockholders, including proposals related to reverse stock splits and authorized share counts. They outline voting procedures, meeting logistics, and the rationale behind capital structure decisions. Together with other periodic and transactional filings, these documents help explain how SeaStar Medical manages its equity, governance, and financing as it advances SCD-based therapies.
On Stock Titan, SeaStar Medical’s filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the key points in complex filings, helping readers quickly understand topics such as trial-related disclosures, compensation arrangements for executives, and the impact of corporate actions on ICU common stock and ICUCW warrants. Users can also review filings that reference the company’s Breakthrough Device Designations, Humanitarian Device Exemption framework for QUELIMMUNE, and pivotal trial plans, gaining a structured view of how regulatory and clinical developments intersect with SeaStar Medical’s capital markets activity.
SeaStar Medical Holding Corporation is asking stockholders to vote at its virtual 2026 annual meeting on four key items. Stockholders will elect one Class I director, John Neuman, to serve until the 2029 annual meeting, and vote on an expanded equity plan.
The company seeks approval to amend and restate its 2022 Equity Incentive Plan to increase authorized common shares under the plan from 207,046 to 896,546, following a 1-for-10 reverse stock split effective January 5, 2026. Stockholders will also vote on ratifying WithumSmith+Brown, PC as independent auditor for 2026 and on a possible adjournment of the meeting if more time is needed to gather votes. As of April 24, 2026, 3,997,002 shares of common stock were outstanding and entitled to one vote per share.
SeaStar Medical Holding Corporation filed Post-Effective Amendment No. 5 to its Form S-1 to register up to 65,068 shares of Common Stock for resale by selling securityholders, consisting of (i) up to 22,952 Private Placement Warrant Shares, (ii) up to 2,800 PIPE Warrant Shares and (iii) 39,316 other shares. The company states it will receive proceeds only if the Warrants are exercised; full cash exercise of all Warrants would generate approximately $74.0 million. SeaStar discloses prior reverse stock splits (1-for-25 in 2024; 1-for-10 in 2026), Nasdaq listings under symbols ICU and ICUCW, and that 3,997,002 shares were outstanding as of April 20, 2026. The filing also reports the dismissal with prejudice of a putative class action on April 27, 2026 and ongoing derivative litigation that remains stayed or unresolved.
SeaStar Medical Holding Corporation amends its effective Form S-1 to register for resale up to 1,091,730 shares of Common Stock issuable upon exercise of certain private placement and placement-agent warrants (the “Resale Shares”).
The prospectus states the resale registration covers: up to 524,249 July Common Warrant Shares, 36,699 July Placement Agent Warrant Shares, 496,057 August Common Warrant Shares and 34,725 August Placement Agent Warrant Shares. The company will not receive proceeds from resales by the selling securityholders but would receive proceeds from any cash exercises of the Warrants. Shares outstanding were 3,997,002 as of April 20, 2026.
SeaStar Medical Holding Corporation files a Post-Effective Amendment No. 1 to its Form S-1 to incorporate by reference prior and future SEC filings and to update the prospectus; no additional securities are being registered in this amendment. The prospectus covers an offering that includes 493,542 shares of Common Stock, accompanying Series A and Series B Warrants, 66,232 Pre-Funded Warrants, and 43,079 Placement Agent Warrants, together representing 1,340,091 shares issuable upon exercise. The filing restates offering terms (combined offering price $6.50 per share/unit; Pre-Funded Warrant price $6.499), notes a 1-for-10 reverse split effective January 5, 2026, and discloses that a putative class action and a derivative action were dismissed (the class complaint was dismissed with prejudice by court order on April 27, 2026). The prospectus states estimated net proceeds of approximately $3.39 million under specified assumptions and that aggregate cash proceeds on full cash exercise of outstanding warrants would be approximately $8.4 million.
SeaStar Medical Holding Corporation is filing an S-1 to register the resale of up to 1,664,543 shares of common stock held by Lincoln Park Capital Fund LLC. These shares relate to a previously signed $15.0 million equity purchase agreement, under which SeaStar can periodically sell stock to Lincoln Park.
SeaStar will not receive proceeds from Lincoln Park’s resale of these registered shares, but may receive up to an additional $14,657,887.43 in gross proceeds from future share sales to Lincoln Park under the agreement. As of April 20, 2026, the company had 3,997,002 shares outstanding, and sales under this structure, alongside past at-the-market offerings, could dilute existing holders.
The filing also describes SeaStar’s commercial-stage inflammatory disease platform, including its FDA-approved pediatric SCD therapy under a Humanitarian Device Exemption, multiple Breakthrough Device Designations, and ongoing adult clinical programs targeting acute kidney injury and cardiorenal indications.
SeaStar Medical Holding Corporation reports that a previously filed federal securities class action against the company and certain executives has been dismissed with prejudice. The lawsuit, filed in 2024, had alleged misstatements or omissions related to the company’s business, operations and a prior financial restatement.
After the parties submitted a stipulation of dismissal on April 21, 2026, the United States District Court for the District of Colorado ordered on April 27, 2026 that the case be dismissed with prejudice. This ruling closes the putative class action without the option for the same claims to be refiled.